Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

Cancer is a leading cause of morbidity and mortality worldwide. Over the past decades, the
concept of precision cancer medicine has emerged as a novel approach in the field of …

Background There is an extensive literature highlighting the utility of blood-based liquid
biopsies in several extracranial tumors for diagnosis and monitoring. Methods The RANO …

The treatment scenario for patients with resectable non–small cell lung cancer has changed
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …

Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive
biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in …

Body fluids are constantly replenished with a population of genetically diverse cell-free DNA
(cfDNA) fragments, representing a vast reservoir of information reflecting real-time changes …

Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid
biopsy-based testing has proven to be highly beneficial for identifying actionable cancer …

Tumor-derived circulating cell-free DNA (cfDNA) provides critical clues for cancer early
diagnosis, yet it often suffers from low sensitivity. Here, we present a cancer early diagnosis …

Survival for glioma patients has shown minimal improvement over the past 20 years. The
ability to detect and monitor gliomas relies primarily upon imaging technologies that lack …

Background A family history of pancreatic cancer is associated with increased pancreatic
cancer risk. However, risk estimates for individuals in kindreds with an aggregation of …